[go: up one dir, main page]

WO2000066577A3 - Ligands de thromboxane sans effets secondaires de coagulation du sang - Google Patents

Ligands de thromboxane sans effets secondaires de coagulation du sang Download PDF

Info

Publication number
WO2000066577A3
WO2000066577A3 PCT/US2000/011760 US0011760W WO0066577A3 WO 2000066577 A3 WO2000066577 A3 WO 2000066577A3 US 0011760 W US0011760 W US 0011760W WO 0066577 A3 WO0066577 A3 WO 0066577A3
Authority
WO
WIPO (PCT)
Prior art keywords
radical
group
radicals
aryl
hemorrhage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2000/011760
Other languages
English (en)
Other versions
WO2000066577A2 (fr
Inventor
Robert M Burk
Achim H Krauss
David F Woodward
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Sales LLC
Original Assignee
Allergan Sales LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Sales LLC filed Critical Allergan Sales LLC
Priority to AU46875/00A priority Critical patent/AU4687500A/en
Publication of WO2000066577A2 publication Critical patent/WO2000066577A2/fr
Publication of WO2000066577A3 publication Critical patent/WO2000066577A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
    • C07D319/08—1,3-Dioxanes; Hydrogenated 1,3-dioxanes condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne un procédé de traitement des affections suivantes: hypotension oculaire, hypertension, hémorragie, ischémie myocardique, angine de poitrine, contraction coronarienne, contraction cérébrovasculaire survenant après une hémorragie sous-arachnoïdienne, hémorragie cérébrale et asthme. On administre au mammifère à traiter une quantité thérapeutiquement efficace de ligand de thromboxane qui est un composé de formule (I(a)), les hachures indiquant la configuration α et le triangle en trait plein indiquant la configuration β; Y est (CH2)x; Z peut être (1), O, OCH2, O-C-O et(Cr2)x, x étant un entier valant 1 ou 2; R2 est hydrogène ou un radical alkyle ayant de 1 à 4 atomes de carbone; A est un radical alkylène ou alcénylène ayant de 2 à 7 atomes de carbone, pouvant être substitué par un ou plusieurs groupes hydroxy, oxo, alkyloxy ou alkylcarboxy, et ce radical alkylène ou alcénylène peut comporter un ou plusieurs radicaux oxo ou imino en chaîne; B est un radical méthyle ou cycloalkyle ayant de 3 à 7 atomes de carbone, ou un radical aryle, pouvant être un radical hydrocarbyle aryle et hétéroaryle, sachant que l'hétéroatome peut être azote, oxygène et soufre, ou des dérivés substitués des radicaux considérés, sachant que le substituant peut être halo, nitro, amino, thiol, hydroxy, alkyloxy et alkylcarboxy; et X peut être un radical cyano, -COOR, -CH2OR1, -C(O)N(R1)2, -CH2N(R1)2 -CH=N-OH et -CH2SR1, sachant que R est alkyle C1-10, phényle ou benzyle et que R1 est R ou hydrogène. Il peut aussi s'agir d'un sel pharmaceutiquement acceptable correspondant.
PCT/US2000/011760 1999-04-29 2000-04-27 Ligands de thromboxane sans effets secondaires de coagulation du sang Ceased WO2000066577A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU46875/00A AU4687500A (en) 1999-04-29 2000-04-27 Thromboxane ligands without blood clotting side effects

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30179499A 1999-04-29 1999-04-29
US09/301,794 1999-04-29

Publications (2)

Publication Number Publication Date
WO2000066577A2 WO2000066577A2 (fr) 2000-11-09
WO2000066577A3 true WO2000066577A3 (fr) 2001-03-01

Family

ID=23164906

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/011760 Ceased WO2000066577A2 (fr) 1999-04-29 2000-04-27 Ligands de thromboxane sans effets secondaires de coagulation du sang

Country Status (2)

Country Link
AU (1) AU4687500A (fr)
WO (1) WO2000066577A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0201837D0 (sv) * 2002-06-14 2002-06-14 Astrazeneca Ab Chemical compounds
HUE067954T2 (hu) 2014-05-13 2024-11-28 Novartis Ag Vegyületek és készítmények kondrogenezis indukálására

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4438136A (en) * 1979-01-05 1984-03-20 National Research Development Corporation Prostaglandins
US4654364A (en) * 1984-11-30 1987-03-31 E. R. Squibb & Sons, Inc. Hydroxamic acids of 7-oxabicycloheptane substituted ethers
JPS63284158A (ja) * 1987-05-18 1988-11-21 Shionogi & Co Ltd フェニルスルホニルアミノアルキルビシクロヘプチルヘプテン酸誘導体
US4942256A (en) * 1988-12-13 1990-07-17 National Research Development Corporation Novel intermediates in the manufacture of novel thromboxane A2 antagonists
DE4013680A1 (de) * 1989-05-01 1990-11-08 Squibb & Sons Inc Thromboxan-a(pfeil abwaerts)2(pfeil abwaerts)-rezeptor-antagonisten zur hemmung von vasospasmen und thrombozyten-aggregation aufgrund einer angioplastie
US4973604A (en) * 1988-12-13 1990-11-27 National Research Development Corporation Thromboxane A2 antagonists and pharmaceutical compositions thereof
US4977174A (en) * 1989-06-12 1990-12-11 E. R. Squibb & Sons, Inc. 7-oxabicycloheptane imidazole prostaglandin analogs useful in the treatment of thrombotic and vasospastic disease
JPH0377862A (ja) * 1989-08-18 1991-04-03 Ono Pharmaceut Co Ltd ビシクロ［２．２．１］ヘプタン誘導体、その精製方法および製造方法
WO1995018103A1 (fr) * 1993-12-28 1995-07-06 Allergan 7-[carboxyalkyle ou alcenyle]-6-[alkyle ou alcenyle] 3-oxo-2,4-dioxobicyclo-[3.2.1] octane et ses derives
US5650431A (en) * 1993-12-28 1997-07-22 Allergan Thromboxane ligands without blood clotting side effects
US5741812A (en) * 1993-12-28 1998-04-21 Allergan Thromboxane ligands without blood clotting side effects
WO1999012921A1 (fr) * 1997-09-09 1999-03-18 Allergan Sales, Inc. Ligands a thromboxane

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4438136A (en) * 1979-01-05 1984-03-20 National Research Development Corporation Prostaglandins
US4654364A (en) * 1984-11-30 1987-03-31 E. R. Squibb & Sons, Inc. Hydroxamic acids of 7-oxabicycloheptane substituted ethers
JPS63284158A (ja) * 1987-05-18 1988-11-21 Shionogi & Co Ltd フェニルスルホニルアミノアルキルビシクロヘプチルヘプテン酸誘導体
US4942256A (en) * 1988-12-13 1990-07-17 National Research Development Corporation Novel intermediates in the manufacture of novel thromboxane A2 antagonists
US4973604A (en) * 1988-12-13 1990-11-27 National Research Development Corporation Thromboxane A2 antagonists and pharmaceutical compositions thereof
DE4013680A1 (de) * 1989-05-01 1990-11-08 Squibb & Sons Inc Thromboxan-a(pfeil abwaerts)2(pfeil abwaerts)-rezeptor-antagonisten zur hemmung von vasospasmen und thrombozyten-aggregation aufgrund einer angioplastie
US4977174A (en) * 1989-06-12 1990-12-11 E. R. Squibb & Sons, Inc. 7-oxabicycloheptane imidazole prostaglandin analogs useful in the treatment of thrombotic and vasospastic disease
JPH0377862A (ja) * 1989-08-18 1991-04-03 Ono Pharmaceut Co Ltd ビシクロ［２．２．１］ヘプタン誘導体、その精製方法および製造方法
WO1995018103A1 (fr) * 1993-12-28 1995-07-06 Allergan 7-[carboxyalkyle ou alcenyle]-6-[alkyle ou alcenyle] 3-oxo-2,4-dioxobicyclo-[3.2.1] octane et ses derives
US5516791A (en) * 1993-12-28 1996-05-14 Allergan 7-[carboxyakyl or alkenyl]-6-[alkyl or alkenyl]3-oxo-2,4-dioxobicyclo-[3.2.1]octane and derivatives thereof
US5650431A (en) * 1993-12-28 1997-07-22 Allergan Thromboxane ligands without blood clotting side effects
US5741812A (en) * 1993-12-28 1998-04-21 Allergan Thromboxane ligands without blood clotting side effects
WO1999012921A1 (fr) * 1997-09-09 1999-03-18 Allergan Sales, Inc. Ligands a thromboxane

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PATENT ABSTRACTS OF JAPAN vol. 013, no. 107 14 March 1989 (1989-03-14) *
PATENT ABSTRACTS OF JAPAN vol. 015, no. 248 25 June 1991 (1991-06-25) *

Also Published As

Publication number Publication date
AU4687500A (en) 2000-11-17
WO2000066577A2 (fr) 2000-11-09

Similar Documents

Publication Publication Date Title
EP1052254A4 (fr) Derives heterocycliques azotes et medicaments produits a partir de ces derives
PL361426A1 (pl) Związki z grupą sulfonamidową oraz kompozycje farmaceutyczne zawierające te związki
RU2006105804A (ru) Нитрооксипроизводные лозартана, валсартана, кандесартана, телмисартана, эпросартана и олмесартана в качестве блокаторов рецепторов ангиотензина ii для лечения сердечно-сосудистых заболеваний
MXPA04000411A (es) Tiazolidinonas arilo sustituidas y uso de las mismas.
KR960705777A (ko) 산화질소 신타제 저해제로서 유용한 아미디노유도체(amidino derivatives useful as nitric oxide synthase inhibitors)
CA2551409A1 (fr) Nitro-oxy-derives de la prostaglandine
EE200100513A (et) Rakkude adhesiooni inhibeerivad põletikuvastased ja immunosupressiivsed ühendid
TR200000837A2 (tr) Anti-kanser bileşimleri hazırlamak için işlem ve ara maddeler.
KR950000659A (ko) 항-고콜레스테롤혈증 활성을 갖는 아미드 및 우레아 유도체, 그의 제조방법 및 그의 치료학적 용도
JP2008520811A5 (fr)
RU2005115964A (ru) Производные 1-(4-бензилпиперазин-1-ил)-3-фенилпропенона
RU2005116248A (ru) 9а-азалиды с противовоспалительной активностью
WO2000066577A3 (fr) Ligands de thromboxane sans effets secondaires de coagulation du sang
JP2006504673A5 (fr)
KR950704325A (ko) 류코트리엔 길항제로서의 디아릴 5,6-융합된 헤테로사이클릭산(Diaryl 5,6-fusesheterocyclic acids as leukotriene antagonists)
WO2004071428A3 (fr) Derives de l'acide 10,10-dialkyl-prostanoique utilises comme agents reducteurs de la pression intraoculaire
KR900018082A (ko) 페닐알카노산의 에스테르
EA007068B1 (ru) S-метилдигидрозипразидон для лечения психических заболеваний
AR050043A1 (es) Metodos para mejorar la biodisponibilidad y composicion farmaceutica para trastornos cardiovasculares
RU97116496A (ru) Аналоги аргинина, ингибирующие no-синтазу
WO2006121822B1 (fr) Utilisation de $g(b)-lactames pour traiter la maladie intestinale inflammatoire et le glaucome
WO2006113571B1 (fr) Cyclopentanones substitues a usage therapeutique
ES2080564T3 (es) Composicion mejoradora del metabolismo de los lipidos.
CA2244695A1 (fr) Derives d'acides d'amides cycliques
ATE271052T1 (de) Wasserlösliche sdz-rad ester

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP